New oral therapy shows early signs of safety and effectiveness in patients with advanced, treatment-resistant prostate cancer
Trial shows promising early results for HLD-0915, a first-in-class regulated induced proximity targeting chimera (RIPTAC) treatment
Metastatic castration-resistant prostate cancer (mCRPC) is a hard-to-treat prostate cancer that no longer responds to standard hormone therapy
Preliminary data suggest HLD-0915 has a favorable safety profile with evidence of tumor shrinkage and PSA decline in mCRPC patients
HLD-0915 received FDA fast track...
Study shows protein relieves pain hypersensitivity in preclinical models
Scientists find new role for LRRC8A protein in regulating pain
Increasing LRRC8A expression reduced pain hypersensitivity in preclinical models...
Spatial analysis finds immune-rich pockets in diffuse large B-cell lymphoma tumors with clear treatment potential
Study identified seven distinct and unique microenvironments within diffuse large B-cell lymphoma (DLBCL)
Immune-privileged DLBCLs...
ESMO 2025: VT3989 continues to show promising early results in patients with advanced mesothelioma
VT3989 is a first-in-class YAP-TEAD inhibitor from Vivace Therapeutics that is currently in Phase I/II trials for patients with advanced solid tumors, with a focus on refractory mesothelioma
In this trial, VT3989 demonstrated notable antitumor activity, with a disease control rate of 86% at the clinically optimized dosing levels
These data provide the first clinical proof-of-concept for effectively drugging the Hippo-YAP-TEAD pathway
VT3989...
ESMO 2025: mRNA-based COVID vaccines generate improved responses to immunotherapy
Cancer patients who received mRNA COVID vaccines within 100 days of starting immunotherapy were twice as likely to be alive three years after...
ESMO 2025: Dual targeted therapy shows promise in previously treated advanced kidney cancer patients
Study found patients treated with combination of lenvatinib and everolimus lived longer without disease progression
First head-to-head study...
ESMO 2025: Trial results show belzutifan shrinks rare neuroendocrine tumors and improves symptoms in patients
Pheochromocytoma and paraganglioma (PPGL) are rare, hard-to-treat neuroendocrine tumors that form in the adrenal glands or in the extra-adrenal...
ESMO 2025: Oral drug demonstrates promising anti-tumor activity in patients with advanced lung cancer
Lung cancer is the leading cause of cancer-related death worldwide, with up to 4% of non-small cell lung cancer cases having a HER2 gene...
ESMO 2025: Targeted therapy plus radiation or surgery improves outcomes in patients with advanced lung cancer
Lung cancer is the leading cause of cancer-related death worldwide, with non-small cell lung cancer (NSCLC) the most common form?
Study reveals how bacteria in tumors drive treatment resistance in cancer
Researchers uncovered a previously unknown way for microbes within tumors to contribute to treatment resistance in certain cancers...
Researchers find new biomarker for improved immunotherapy response in solid tumors
Study uncovers novel relationship between TET2-mutated white blood cells and antitumor immune responses
TET2-mutated clonal hematopoiesis is...
Researchers identify genetic markers that affect treatment outcomes in patients with large B-cell lymphoma
Multiple genetic markers play a key role in the treatment outcomes of patients with large B-cell lymphoma (LBCL) who received chimeric antigen...
Stem cell transplant achieves positive outcomes in second remission for adolescents and young adults with ALL
A new study from Â鶹ӳ» MD Anderson Cancer Center and Dana-Farber Cancer Institute, published in American Journal of Hematology...
New computational method improves ability to detect precancerous tissues
CoCo-ST is a novel method of mapping tissues that is superior to current state-of-the-art benchmarks in preclinical models
Technique allows...